ADMA Biologics (NASDAQ:ADMA) Stock Price Down 3.2%

ADMA Biologics, Inc. (NASDAQ:ADMA)’s share price fell 3.2% during mid-day trading on Tuesday . The company traded as low as $19.30 and last traded at $19.39. 601,865 shares changed hands during mid-day trading, a decline of 83% from the average session volume of 3,458,099 shares. The stock had previously closed at $20.03.

Wall Street Analyst Weigh In

ADMA has been the subject of a number of research analyst reports. Mizuho raised their target price on ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. HC Wainwright lifted their price objective on shares of ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $15.50.

ADMA Biologics Trading Down 4.4 %

The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. The company’s 50 day simple moving average is $15.90 and its two-hundred day simple moving average is $11.10. The company has a market cap of $4.44 billion, a PE ratio of -1,001.50 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. ADMA Biologics’s revenue was up 78.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.02) earnings per share. As a group, sell-side analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at $2,843,290.27. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $16.90, for a total transaction of $408,135.00. Following the completion of the sale, the chief operating officer now owns 449,088 shares of the company’s stock, valued at $7,589,587.20. The disclosure for this sale can be found here. In the last quarter, insiders sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. increased its holdings in shares of ADMA Biologics by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 29,192 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 5,465 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in ADMA Biologics by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock worth $7,398,000 after buying an additional 27,357 shares during the period. BNP Paribas Financial Markets grew its holdings in ADMA Biologics by 49.8% during the 4th quarter. BNP Paribas Financial Markets now owns 290,605 shares of the biotechnology company’s stock worth $1,314,000 after acquiring an additional 96,653 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of ADMA Biologics by 17.7% in the 4th quarter. Principal Financial Group Inc. now owns 158,634 shares of the biotechnology company’s stock worth $717,000 after purchasing an additional 23,844 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its holdings in ADMA Biologics by 20.2% during the 4th quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 4,367 shares in the last quarter. 75.68% of the stock is owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.